CALIX INC
For the period ended Sep 28, 2024. Filed Oct 29, 2024.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Sep 28, 2024 · Filed Oct 29, 2024
CALX$32.24+0.2%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Condensed Consolidated Statements of Cash Flows
(In thousands, unaudited)
| Nine Months Ended | ||
|---|---|---|
| September 28,2024 | September 30,2023 | |
| Operating activities: | ||
| Net income (loss) | $(11,823) | $35,924 |
| Adjustments to reconcile net income (loss) to net cash provided by operating activities: | ||
| Stock-based compensation | 48,686 | 50,090 |
| Depreciation and amortization | 14,805 | 12,181 |
| Deferred income taxes | (10,420) | 4,294 |
| Net accretion of available-for-sale securities | (3,958) | (3,119) |
| Changes in operating assets and liabilities: | ||
| Accounts receivable, net | 40,755 | 13,143 |
| Inventory | 32,376 | (873) |
| Prepaid expenses and other assets | 7,659 | (48,532) |
| Accounts payable | (11,809) | (19,756) |
| Accrued liabilities | (39,768) | (141) |
| Deferred revenue | (10,636) | 1,745 |
| Other long-term liabilities | (2,830) | (3,629) |
| Net cash provided by operating activities | 53,037 | 41,327 |
| Investing activities | ||
| Purchases of property and equipment | (12,905) | (13,883) |
| Purchases of marketable securities | (228,456) | (133,521) |
| Sales of marketable securities | 49,905 | — |
| Maturities of marketable securities | 115,529 | 185,888 |
| Net cash provided by (used in) investing activities | (75,927) | 38,484 |
| Financing activities: | ||
| Proceeds from common stock issuances related to employee benefit plans | 25,433 | 26,659 |
| Repurchases of common stock | (3,738) | (42,409) |
| Payments related to financing arrangements | — | (7,560) |
| Net cash provided by (used in) financing activities | 21,695 | (23,310) |
| Effect of exchange rate changes on cash and cash equivalents | 147 | 101 |
| Net increase (decrease) in cash and cash equivalents | (1,048) | 56,602 |
| Cash and cash equivalents at beginning of period | 63,409 | 79,073 |
| Cash and cash equivalents at end of period | $62,361 | $135,675 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.